After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences ...

May 29, 2025 — Researchers have developed a way to edit the genetic sequences at the root of Huntington's disease and Friedreich's ataxia. If longer than a certain threshold length, ...